Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 75 |
| Active Pipeline (Recruiting Now) | 40 (23) |
| Completed vs Stopped Early | 14 / 21 (28.0%) |
| Median Closed Actual Enrollment | 24 participants |
| Physical Hospital Site Disclosure | 100.0% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| Weill Cornell Medicine | New York, NY | 65 |
| Ohio State University Comprehensive Cancer Center | Columbus, OH | 5 |
| Columbia University Irving Medical Center | New York, NY | 5 |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT03804944 | Converting HR+ Breast Cancer Into an Individualized Vaccine | Phase II | RECRUITING |
| NCT06994442 | Optimizing Pain Treatment in Children On Mechanical Ventilation | Phase III | RECRUITING |
| NCT05997693 | One-Month DAPT in CABG Patients | Phase III | RECRUITING |
| NCT06399705 | REvascularization CHoices Among Under-Represented Groups Evaluation: The RECHARGE Trial - Minorities | Phase III | RECRUITING |
| NCT06399692 | REvascularization CHoices Among Under-Represented Groups Evaluation: The RECHARGE Trial - Women | Phase III | RECRUITING |
Explore interactive annual charts and M&A subsidiary rollups in the Weill Medical College of Cornell University Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.